clonazepam (klonopin) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Clonazepam, a benzodiazepine, is used primarily as an anticonvulsant in the treatment of absence seizures, petit mal variant seizures (Lennox-Gastaut syndrome), akinetic and myoclonic seizures, and nocturnal myoclonus. Klonopin is the brand name for Clonazepam, an anxiolytic and anticonvulsant. The precise mechanism by which clonazepam exerts its antiseizure and antipanic effects is unknown, although it is believed to be related to its ability to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. Allosteric interactions between central benzodiazepine receptors and gamma-aminobutyric acid (GABA) receptors potentiate the effects of GABA. As GABA is an inhibitory neurotransmitter, this results in increased inhibition of the ascending reticular activating system. Benzodiazepines, in this way, block the cortical and limbic arousal that occurs following stimulation of the reticular pathways.   NCATS

Chemistry

  • SMILES: [O-][N+](=O)C1=CC=C2NC(=O)CN=C(C3=CC=CC=C3Cl)C2=C1
  • InChIKey: DGBIGWXXNGSACT-UHFFFAOYSA-N
  • Mol. Mass: 315.711
  • ALogP: 3.04
  • ChEMBL Molecule:
    clonazepam  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.0161 - $8.7110

Australia

$0.0442 - $2.9074
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1,3-dihydro-7-nitro-5-(2-chlorophenyl)-2h-1,4.benzodiazepin-2-one | 5-(2-chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one | 5-(2-chlorophenyl)-7-nitro-1h-benzo[e][1,4]diazepin-2(3h)-one | 5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2h-1,4-benzodiazepin-2-one | cloazepam | clonazepam | clonazepamum | klonopin | klonopin rapidly disintegrating | lonazep | rivotril | ro-54023 | ro-5-4023

Organizations (68)

Research & Development (51)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (18)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (27)

Approved Indications (3)


 

Epilepsy (approved 1975)

Panic Disorder (approved 1975)

Seizures

Experimental Indications - Clinical Trial Phases 1-4 (26)


 

Agoraphobia (Phase 4)

Anxiety Disorders (Phase 3)

Burning Mouth Syndrome (Phase 4)

Cannabis (Phase 2)

Cerebral Palsy (Phase 4)

Crying (Phase 4)

Dementia (Phase 3)

Depression (Phase 3)

Drug Resistant Epilepsy (Phase 4)

Drugs, Generic (Phase 1)

Epilepsia Partialis Continua (Phase 3)

Epilepsy ()

Glossalgia (Phase 2)

Heart Arrest (Phase 4)

Neuralgia (Phase 1/Phase 2)

Pain (Phase 4)

Panic Disorder (Phase 4)

Parkinson Disease (Phase 2)

Pharmacokinetics (Phase 1)

Phobia, Social (Phase 4)

Psychophysiologic Disorders (Phase 3)

Psychotic Disorders (Phase 4)

REM Sleep Behavior Disorder (Phase 2)

Schizophrenia (Phase 4)

Status Epilepticus (Phase 3)

Stress Disorders, Post-Traumatic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 33
  • # of Trial Organizations: 51

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue